Novo Nordisk: to restructure R&D; lays off 400 workers
(CercleFinance.com) - Danish drugmaker Novo Nordisk is transforming its approach to research and development (R&D), leading to the layoff of 400 employees - mainly in Denmark and China, the company said on Tuesday.
The firm today announced plans to restructure its R&D organisation to accelerate the expansion and diversification of its pipeline across serious chronic diseases.
This means increased investments in biological and technological innovation within both core and new therapy areas, which has resulted in the job cuts, the company said.
Starting in 2018, Novo will establish four research units to pursue novel treatment modalities and platform technologies. The biotech-like units, based in Denmark, the US and the UK, will operate as satellites of the group's central R&D division, mostly in cardio-metabolic research and stem cell research.
Furthermore, the company will increase its investment in automation and digital capabilities including machine learning and artificial intelligence (AI).
Earlier this year, Novo had announced the acquisition of the UK-based biotech start-up Ziylo to enhance research within glucose-responsive insulins.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The firm today announced plans to restructure its R&D organisation to accelerate the expansion and diversification of its pipeline across serious chronic diseases.
This means increased investments in biological and technological innovation within both core and new therapy areas, which has resulted in the job cuts, the company said.
Starting in 2018, Novo will establish four research units to pursue novel treatment modalities and platform technologies. The biotech-like units, based in Denmark, the US and the UK, will operate as satellites of the group's central R&D division, mostly in cardio-metabolic research and stem cell research.
Furthermore, the company will increase its investment in automation and digital capabilities including machine learning and artificial intelligence (AI).
Earlier this year, Novo had announced the acquisition of the UK-based biotech start-up Ziylo to enhance research within glucose-responsive insulins.
Copyright (c) 2018 CercleFinance.com. All rights reserved.